Pa Vmed Inc. PAVM
We take great care to ensure that the data presented and summarized in this overview for PAVmed Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PAVM
View allLatest Institutional Activity in PAVM
Top Purchases
Top Sells
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Insider Transactions at PAVM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Feb 22
2024
|
Ronald M Sparks Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+50.0%
|
-
|
|
Feb 22
2024
|
Michael J Glennon Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+17.11%
|
-
|
|
Feb 22
2024
|
Debra White Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+50.0%
|
-
|
|
Feb 22
2024
|
Timothy E Baxter Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+50.0%
|
-
|
|
Feb 22
2024
|
Joan B Harvey Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+50.0%
|
-
|
|
Feb 22
2024
|
James L Cox Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+50.0%
|
-
|
|
Dec 07
2022
|
Michael J Glennon Director |
BUY
Open market or private purchase
|
Direct |
100,000
+28.57%
|
$0
$0.62 P/Share
|
|
Dec 06
2022
|
Michael J Glennon Director |
BUY
Open market or private purchase
|
Direct |
88,000
+36.97%
|
$0
$0.64 P/Share
|
|
Dec 05
2022
|
Michael J Glennon Director |
BUY
Open market or private purchase
|
Direct |
62,000
+50.0%
|
$0
$0.69 P/Share
|
|
May 04
2022
|
Shaun O'Neil Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,935
-8.9%
|
$25,935
$1.38 P/Share
|
|
Mar 28
2022
|
Lishan Aklog Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
79,636
-31.12%
|
$79,636
$1.18 P/Share
|
|
Mar 28
2022
|
Dennis M Mcgrath President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
199,973
-20.93%
|
$199,973
$1.18 P/Share
|
|
Feb 22
2022
|
Shaun O'Neil Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
75,000
-33.33%
|
$150,000
$2.43 P/Share
|
|
Apr 01
2021
|
Lishan Aklog Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+10.67%
|
-
|
|
Apr 01
2021
|
Dennis M Mcgrath President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+13.57%
|
-
|
|
Mar 18
2021
|
Lishan Aklog Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
7,500
+0.67%
|
$30,000
$4.31 P/Share
|
|
Nov 25
2020
|
Matthew Sirovich > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
33,203
-3.13%
|
$33,203
$1.96 P/Share
|
|
Nov 24
2020
|
Matthew Sirovich > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
53,036
-4.76%
|
$106,072
$2.0 P/Share
|
|
Nov 19
2020
|
Matthew Sirovich > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
75,211
-6.32%
|
$75,211
$1.83 P/Share
|
|
Nov 18
2020
|
Matthew Sirovich > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
24,789
-2.04%
|
$24,789
$1.78 P/Share
|